Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Recurrence 1Neurofibrosarcoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Nonhematological Neoplasms 1

Interventions

Sorafenib 12Radiosurgery 5Gemcitabine 5Capecitabine 5Bevacizumab 5Radiotherapy 4Fluorouracil 4Doxorubicin 4Sunitinib 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3seocalcitol 2regorafenib 2phosphomannopentaose sulfate 2atezolizumab 2Thiotepa 2Radiofrequency Ablation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Dexamethasone 2Cisplatin 2Chemoembolization, Therapeutic 2Carboplatin 2Busulfan 2Brachytherapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Liver Neoplasms × sapanisertib × Clear all
NCT02575339 2022-07-26

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Big Ten Cancer Research Consortium

Phase 1/2 Terminated
11 enrolled 15 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡